Skip to main content
Medicines, medical devices

Guidance and regulation

Skip to results
399 results sorted by Most viewed
  • Guidance and advice for community pharmacies in England providing services to people who use drugs and alcohol.

  • Guidance for dispensing of valproate-containing medicines in the manufacturer’s original full pack, following amendments to the Human Medicines Regulations (HMRs).

  • How to use RamaXL, including system availability, running reports and how to subscribe.

  • Advice and guidance on the management and use of point-of-care testing (POCT) in vitro diagnostic (IVD) devices.

  • Provide innovators and developers of innovative products access to MHRA scientific expertise, regulatory guidance and an enhanced advice and signposting service.

  • How to best protect patients and volunteers during magnetic resonance imaging (MRI) examinations.

  • Instructions for integrating with the new production MORE platform API.

  • A 5-year voluntary scheme on the control of prices agreed between government and the Association of the British Pharmaceutical Industry (ABPI).

  • From discovery to real-world impact, VDEC equips scientists with the expertise and facilities to navigate each step in the development of vaccines and therapeutics.

  • VDEC works with global leaders from all sectors to develop and deliver the vaccine and therapeutic products we need to protect us from infectious diseases.

  • Sets out the process for pharmaceutical companies to appeal against decisions made by the Secretary of State for Health and Social Care.

  • UKHSA offers a unique opportunity to harness world-class intellectual, scientific, and operational expertise for public health solutions.

  • Information for manufacturers and users of medical devices containing plastic with DEHP phthalates.

  • Submitting annual reports on sales of electronic cigarettes and refill containers.

  • Guidance for hospital blood banks on issuing blood components electronically in line with best practice.

  • Information for patients who have been prescribed Lagevrio (molnupiravir), the COVID-19 oral antiviral medication.

  • Information and advice on submitting a dermatological product to the Advisory Committee for Borderline Substances (ACBS).

  • Resources for pharmacies to achieve Healthy Living Pharmacy (HLP) Level 1 status.

  • Deficiencies in Omega’s pharmacovigilance system are not thought to affect the safety of the products that they market.

  • How to comply with the regulations when using a medical device differently to the manufacturer's instructions.